Hepatitis C Counseling and Rapid Testing Guidelines
TABLE OF CONTENTS

Purpose ........................................................................................................................................................................... 2
Goals .............................................................................................................................................................................. 2
Considerations prior to implementing rapid HCV testing .......................................................................................... 2
  CLIA certification ....................................................................................................................................................... 2
  Staff qualification and training .................................................................................................................................. 3
  Communicable disease reporting ............................................................................................................................... 5
  Medical referrals ....................................................................................................................................................... 5
HCV Overview ............................................................................................................................................................ 6
  Transmission .............................................................................................................................................................. 9
  Risk ......................................................................................................................................................................... 10
  Treatment ............................................................................................................................................................... 10
  Diagnosis ............................................................................................................................................................... 10
  Prevention ............................................................................................................................................................ 12
Protocol for performing rapid HCV testing .................................................................................................................. 12
  Client assessment .................................................................................................................................................... 12
  Pre-test counseling ................................................................................................................................................ 13
  Specimen collection .............................................................................................................................................. 14
  Reporting of results and post-test counseling ....................................................................................................... 14
  Referral process .................................................................................................................................................... 15
References .................................................................................................................................................................... 17

Appendices .................................................................................................................................................................. 18

  Appendix A - MDHHS contact information ............................................................................................................ 19
  Appendix B - Rapid HCV testing procedures .......................................................................................................... 20
  Appendix C - Hepatitis C resources .......................................................................................................................... 24
  Appendix D - Local health department listing .................................................................................................... 25
  Appendix E - Rapid HCV reporting form and summary sheet ................................................................................ 26
  Appendix F - Sample client non-reactive results reporting form ........................................................................ 28
  Appendix G - Sample client reactive results reporting form and referral form ................................................... 29
  Appendix H - Other client referral resources ........................................................................................................ 30
  Appendix I - Sample HCV Risk Assessment Form .................................................................................................. 31
  Appendix J - Facility preparation checklist .......................................................................................................... 32
PURPOSE

The purpose of this document is to provide guidance regarding rapid testing for Hepatitis C (HCV). With this new technology, HCV testing will likely be offered in new settings and by new providers with limited previous experience in conducting HCV antibody testing, providing appropriate counseling to clients regarding test results and risk reduction strategies, or reporting communicable disease data to public health. This document outlines recommended actions for venues planning on initiating rapid HCV testing, background information on hepatitis C, recommendations regarding pre- and post-test counseling and risk reduction communication, as well as guidance regarding data collection, reporting and medical referrals.

GOALS

1) Improve knowledge regarding hepatitis C
2) Provide logistical recommendations for venues planning to implement rapid HCV testing
3) Ensure that individuals receiving rapid HCV testing are provided with information regarding hepatitis C transmission and prevention, and receive appropriate risk-reduction counseling
4) Ensure that individuals understand the meaning of their HCV test results
5) Ensure that individuals with reactive rapid HCV test results are successfully referred for confirmatory HCV nucleic acid testing and a medical evaluation by a liver or infectious disease specialist physician.
6) Ensure that individuals with reactive rapid HCV test results receive education regarding liver health and appropriate preventative care
7) Ensure that reactive rapid HCV test results are reported to the local health department, and to the client’s primary care provider if applicable

CONSIDERATIONS PRIOR TO IMPLEMENTING RAPID HCV TESTING

CLIA certification

The Federal Clinical Laboratory Improvement Amendments (CLIA) of 1988 are federal regulations that establish requirements for performing laboratory tests. Under CLIA, a clinical laboratory is defined as any facility that examines materials derived from the human body for the purpose of providing information for the diagnosis, prevention or treatment of any disease or impairment of, or the assessment of the health of, human beings. Any facility that means this definition must have the appropriate CLIA certificate to perform laboratory tests. If a facility is only collecting specimens, a CLIA certificate is not required. The OraQuick HCV Rapid Antibody Test is classified as “waived” under CLIA. The federal agency that regulates CLIA certification is the Center for Medicare and Medicaid Services (CMS). Both federal and state regulations require that any facility performing this test must apply for and receive a CLIA Certificate of Waiver prior to beginning testing. The cost of the certificate is $150.00 every two years.

Visit [http://www.michigan.gov/lara/0,4601,7-154-63294_72971_78688---,00.html](http://www.michigan.gov/lara/0,4601,7-154-63294_72971_78688---,00.html) for further information on CLIA and directions on how to apply for a Certificate of Waiver.
**Bloodborne pathogen exposure**

The FDA-approved rapid HCV testing currently requires collection of blood samples. Standard (universal) precautions should be followed in handling these specimens, i.e., all blood samples should be handled as if they could contain a potentially infectious organism. Furthermore, federal law and state regulations require that facilities collecting blood samples comply with the U.S. Department of Labor Occupational Health and Safety Administration (OSHA) Bloodborne Pathogens standard.

The Michigan Occupational Health and Safety Administration (MIOSHA) has also issued standards to this effect. Requirements include training for all employees with occupational exposure, development of an exposure control plan, provision of personal protective equipment, employee training, post-exposure evaluation and follow-up, hepatitis B vaccination provision, and containment and disposal of bio-hazardous waste.


**Legal considerations**

Facilities planning to initiate testing must identify a medical authority who will provide standing delegation orders for the rapid HCV antibody test. Legal implications of conducting laboratory tests should be reviewed and assurances should be made that the appropriate liability/insurance coverage is in place for this activity.

**Quality assurance**

Although waived rapid HCV antibody tests are simple to use and can provide reliable results when the manufacturer’s directions are followed, mistakes can occur at any point in the testing process. Implementing a quality assurance (QA) program can reduce mistakes. A QA program is a set of planned, step-by-step activities that ensure that kit controls are properly stored at correct temperatures, testing is being carried out correctly, results are accurate, and mistakes are found and corrected to avoid adverse outcomes. Information regarding storage of kit controls can be found in the HCV Rapid Antibody Test package insert. The FDA requires that any facility performing CLIA-waived rapid HIV antibody testing have a quality assurance program in place. While this is not a requirement for rapid HCV antibody testing, it is a recommended practice. Further guidance regarding QA can be found at: [https://www.cdc.gov/hiv/pdf/testing_QA_Guidlines.pdf](https://www.cdc.gov/hiv/pdf/testing_QA_Guidlines.pdf)

**Staff qualifications and training**

**Test kit proficiency**

All staff performing HCV rapid testing must be fully trained in test performance prior to implementation. This training should be documented in the personnel record. Training should include proficiency in
collecting the sample, conducting the test, and interpreting the results of the test and the controls. Proficiency should be reassessed on a regular basis. Training or technical assistance on the test device can be arranged by contacting the local manufacturer representative. Details regarding testing procedure are available in the package insert and in Appendix B. The “Ready Set Go” module developed by CDC with regard to CLIA-waived testing should be reviewed and is available at: https://wwwn.cdc.gov/clia/resources/waivedtests/pdf/readysettestbooklet.pdf

Client counseling, education and risk reduction

Furthermore, all staff must receive education regarding Hepatitis C in order to field client questions. Optimally, staff should also be able to provide appropriate counseling and risk-reduction messages. A Hepatitis C overview begins on Page 6. Recommendations regarding appropriate pre- and post-test counseling as well as risk reduction messages begin on Page 12. The Centers for Disease Control and Prevention (CDC) developed a HCV counseling and testing manual which is included on the MDHHS Hepatitis C website. Links to this website and other educational resources are listed in Appendix C.

Maintaining client privacy and confidentiality

Facilities should have policies and procedures in place that specify how client privacy and confidentiality will be maintained. A quiet, private space should be available for performing the test, disclosing the results, and counseling. Testing records should be stored in a secure location and/or electronic medical record system with limited access.

Medical records retention

In compliance with The Michigan Public Health Act No. 368, 333.16213, medical records must be retained for a minimum of seven years from the date of service. Medical records are defined by the act as including any information, oral or recorded in any form or medium, that pertains to a patient's health care, medical history, diagnosis, prognosis, or medical condition and therefore would include rapid HCV test results.

Facility and other logistical recommendations

Testing locations should ideally be in an area exclusively dedicated to running tests. These areas should include adequate counter space, consistent room temperature, sufficient lighting, adequate storage area for supplies, proper refrigeration for kit controls, ability to limit access or lock room and allow for the maintenance of client confidentiality and the security of a client’s files.

Considerations should be made to client flow through the testing process. Adequacy of staff should be ensured, particularly in the setting of delivering reactive HCV antibody test results and initiating the referral process. At least one staff member who has received training in delivering reactive results and initiating referral process should be present at all times while testing is being conducted.
Reporting HCV results to local health department

Hepatitis C is one of over 90 diseases and conditions that are required to be reported under Michigan Public Health Act No. 368 Communicable Disease Rules: R 325.171-3, 333.5111. In Michigan, positive HCV nucleic acid testing (NAT) results, HCV genotype, reactive standard HCV antibody results and reactive rapid HCV antibody results are therefore reportable by law to the local health department in the jurisdiction where the client resides.

The Privacy Rule in the Health Insurance Portability and Accountability Act of 1996 (HIPAA) allows for the disclosure of protected health information, without individual client or patient authorization, to public health authorities, who are legally authorized to receive such reports for the purpose of preventing or controlling disease.


Prior to initiating testing, facilities should contact the appropriate local health department regarding the preferred method for results reporting. A listing of local health departments is in Appendix D. At a minimum, reported information should include elements in the MDHHS Rapid HCV Reporting Form in Appendix E. Results should be reported within 24 hours.

Importance of medical referrals

It is imperative that facilities conducting rapid HCV antibody testing have the ability to refer clients to appropriate medical and social services. A rapid HCV antibody test indicates that the client was exposed to the HCV virus at some point in their lifetime, but additional testing is needed to determine if the client currently is infected with the virus. In order to establish whether a reactive rapid HCV antibody test result indicates current infection or past infection, confirmatory nucleic acid testing (NAT) must be performed. Individuals with HCV nucleic acid (RNA) present in their blood have current HCV infection, are at risk for development of liver disease (e.g., cirrhosis or liver cancer), should be medically evaluated and may be candidates for curative antiviral treatment. A client with a reactive rapid HCV antibody result must be referred to a licensed health-care provider whose scope of practice includes the authority to order HCV NAT and is able to perform a medical evaluation to assess the client’s liver health. If a client has a primary care provider, (PCP) they can be referred to the PCP office for NAT and liver function testing. However, referral to a hepatologist, gastroenterologist or infectious disease physician is eventually necessary to determine whether the client is a candidate for HCV treatment. Many clients may not have a PCP or health insurance. Local health departments can be contacted for a list of potential providers.

Prior to initiating testing, the facility should identify a provider to whom they can refer clients with reactive results for HCV NAT and medical evaluation if the client does not have a PCP. Optimally, a facility can establish a written memorandum of understanding (MOU) that includes the roles and responsibilities of the referring agency (the testing facility) and the agency accepting the referral. The testing facility should have procedures in place for initiating the referral and tracking the client’s follow-up.
up status. Referrals should be tracked to ensure client access and follow-up. A sample client referral form is available in Appendix G as part of the reactive result client paperwork.

Of note, a review of HCV surveillance data demonstrated that only half of persons reported to public health with a new Hepatitis C diagnosis had HCV NAT that confirmed the diagnosis (CDC MMWR 62;2013). Surveillance data also demonstrates a higher mortality rate among persons who are HCV antibody positive only as compared to those who have had HCV NAT performed. This may be due in part to differences in access to necessary health care. As a result, successful referral to a health-care provider for confirmatory HCV NAT and appropriate preventive services and medical management can have a significant impact on client outcome.

**Other referrals and access to care**

Individuals at-risk for hepatitis C infection may have significant medical comorbidities including STDs, HIV infection and substance abuse. The infrastructure for substance abuse, harm reduction and mental health referrals should be developed. Furthermore, individuals presenting for testing may not have a primary care provider, health insurance and/ or adequate monetary resources to cover the costs of HCV NAT or medical referral. Local sources of assistance with payment for testing, low-cost and free clinics such as federally-qualified health centers (FQHCs), enrollment in insurance through the Affordable Care Act Health Insurance Marketplace, and county health plan information should be available. The local health department can be contacted prior to initiating testing to connect the facility with these locally appropriate resources. Selected referral resources are available in Appendix H.

**Facility protocol/operations manual**

Prior to initiating testing, each facility should develop a site-specific protocol detailing the testing flow, training requirements, referral mechanism, data storage and reporting, CLIA application and bloodborne pathogen exposure.

**HEPATITIS C OVERVIEW**

Staff providing HCV testing and counseling should understand the basic features of hepatitis C, including populations at risk, mode of transmission, laboratory diagnosis, symptoms and complications. It is imperative that testing staff are able to field questions from clients regarding hepatitis C.

Often clients will be confused regarding the differences between hepatitis A, B and C. Clarifying the differences between types of viral hepatitis is important. Facts about viral hepatitis are summarized in Table 1 below.
<table>
<thead>
<tr>
<th></th>
<th>Hepatitis A</th>
<th>Hepatitis B</th>
<th>Hepatitis C</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Caused by</strong></td>
<td>Hepatitis A virus (HAV)</td>
<td>Hepatitis B virus (HBV)</td>
<td>Hepatitis C virus (HCV)</td>
</tr>
<tr>
<td></td>
<td>• Estimated 850,000 - 2.2 million persons living with chronic HBV</td>
<td></td>
<td>• Estimated 2.7-3.9 million persons living with chronic HCV</td>
</tr>
<tr>
<td><strong>Michigan statistics in 2011</strong></td>
<td>70 confirmed infections</td>
<td>• 97 confirmed acute infections</td>
<td>• 32 confirmed acute infections</td>
</tr>
<tr>
<td></td>
<td>• 867 newly diagnosed chronic infections</td>
<td></td>
<td>• 7050 newly diagnosed chronic infections</td>
</tr>
<tr>
<td><strong>How transmitted</strong></td>
<td>Ingestion of fecal material, which can occur with:</td>
<td>Contact with blood, semen, and other bodily fluids containing HBV through:</td>
<td>Contact with blood of infected person through:</td>
</tr>
<tr>
<td></td>
<td>• close or sexual contact with an infected person</td>
<td>• birth to an infected mother</td>
<td>• sharing contaminated needles, syringes, or other injection drug equipment with an infected person</td>
</tr>
<tr>
<td></td>
<td>• eating/drinking contaminated food/beverages</td>
<td>• sexual contact with infected person</td>
<td>Less commonly:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• sharing contaminated needles, syringes or other injection drug equipment with infected person</td>
<td>• sexual contact with infected person</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• needlesticks or sharp medical instrument injuries</td>
<td>• birth to infected mother</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• needlesticks or sharp medical instrument injuries</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• sharing implements for inhaling illicit drugs (e.g., cocaine)</td>
</tr>
<tr>
<td><strong>Who is at risk</strong></td>
<td>• Travelers to areas with intermediate or high rates HAV infection</td>
<td>• Infants of infected mothers</td>
<td>• Current or former injection drug users</td>
</tr>
<tr>
<td></td>
<td>• Sex contacts of infected persons</td>
<td>• Sex partners of infected persons</td>
<td>• Received clotting factor concentrates before 1987</td>
</tr>
<tr>
<td></td>
<td>• Household members or caregivers of infected persons including daycare workers</td>
<td>• Persons with multiple sex partners</td>
<td>• Received blood transfusions or donated organs before July 1992</td>
</tr>
<tr>
<td></td>
<td>• Men who have sex with men</td>
<td>• Persons with a sexually transmitted disease (STD)</td>
<td>• Long-term hemodialysis patients</td>
</tr>
<tr>
<td></td>
<td>• Users of certain illegal drugs (injection and non-injection)</td>
<td>• Men who have sex with men</td>
<td>• Persons with known exposures to</td>
</tr>
<tr>
<td></td>
<td>• Persons with clotting factor disorders</td>
<td>• Injection drug users</td>
<td>• HCV (e.g., healthcare workers after needlesticks, recipients of blood or organs from a donor who later tested positive for HCV)</td>
</tr>
<tr>
<td><strong>Symptoms of acute infection</strong></td>
<td>Fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, yellowing of the skin or eyes (jaundice), gray colored bowel movements, joint pain</td>
<td>Similar for all types of viral hepatitis and can include 1 or more of the following:</td>
<td></td>
</tr>
<tr>
<td><strong>Acute symptoms?</strong></td>
<td>&lt;10% children &lt; 6 yrs 40-50% of children 6-14 70-80% of persons &gt; 14</td>
<td>&lt; 1% of infants &lt; 1 year 5%-15% of children 1-5 years 30%-50% of persons &gt; 5 years</td>
<td>20%-30% of newly infected persons develop symptoms of acute disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chronic infection?</strong></td>
<td>No</td>
<td>&gt;90% of infected infants 25-50% of children 1-5 yrs 6-10% of older children, adults</td>
<td>75-85% of infected persons 15-25% of newly infected persons clear the virus</td>
</tr>
<tr>
<td></td>
<td>Hepatitis A</td>
<td>Hepatitis B</td>
<td>Hepatitis C</td>
</tr>
<tr>
<td>------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Severity</strong></td>
<td>▪ Rarely fatal</td>
<td>▪ Acute HBV infection is rarely fatal</td>
<td>▪ Acute HCV infection is rarely fatal</td>
</tr>
<tr>
<td></td>
<td>▪ Most recover with no residual liver damage</td>
<td>▪ 15-25% of chronically infected will develop chronic liver disease such as cirrhosis, liver failure or liver cancer</td>
<td>▪ 60-70% of chronic infections develop chronic liver disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ 1,800 persons die from HBV-related liver disease each year in the US as documented in death certificates</td>
<td>▪ 5-20% develop cirrhosis over 20-30 yr</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ 1-5% will die from cirrhosis or liver cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ 19,600 deaths in 2014</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>▪ No medication available</td>
<td>Acute: No medication available, supportive treatment</td>
<td>Acute: Antivirals, supportive treatment</td>
</tr>
<tr>
<td></td>
<td>▪ Supportive treatment</td>
<td>Chronic: regular medical monitoring, some patients receive antiviral drugs</td>
<td>Chronic: regular medical monitoring, some patients receive antiviral drugs</td>
</tr>
<tr>
<td><strong>Prevention</strong></td>
<td>Vaccination available:</td>
<td>Vaccination available:</td>
<td>No vaccine available</td>
</tr>
<tr>
<td></td>
<td>▪ 2 doses 6 months apart</td>
<td>▪ Adults: 3 doses over 6 months</td>
<td>Prevention measures:</td>
</tr>
<tr>
<td></td>
<td>▪ Recommended for those at increased risk (above); all infants vaccinated</td>
<td>▪ Children: 3-4 doses over 6-18 months</td>
<td>▪ Don’t share needles to inject drugs, tattooing equipment, razors, toothbrushes, glucose monitors, fingernail clippers</td>
</tr>
<tr>
<td></td>
<td>Prevention measures:</td>
<td>Recommended for those at increased risk (above); all infants vaccinated at birth</td>
<td>▪ Use standard precautions in occupations with possible exposure to blood and body fluids</td>
</tr>
<tr>
<td></td>
<td>▪ Wash hands after using the bathroom, changing a diaper and before preparing, serving or eating food</td>
<td>Prevention measures:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Don’t share needles to inject drugs, tattooing equipment, razors, toothbrushes, glucose monitors, fingernail clippers</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Pregnant women screened for HBV</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Use standard precautions in occupations with possible exposure to blood and body fluids</td>
<td></td>
</tr>
<tr>
<td><strong>Screening for chronic infection recommended for:</strong></td>
<td>Not recommended/not applicable (no chronic infection stage)</td>
<td>▪ All pregnant women</td>
<td>▪ Persons born from 1945–1965</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Persons born in areas with intermediate/high rates HBV infection</td>
<td>▪ Persons who currently inject drugs or who have injected drugs in the past</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ U.S.–born persons not vaccinated as infants whose parents were born in regions with high rates HBV infection</td>
<td>▪ Persons with a history of incarceration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Infants born to HBsAg-positive mothers</td>
<td>▪ Persons with a history of unregulated tattoos or piercings</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Household, needle-sharing, sex contacts of HBsAg-positive persons</td>
<td>▪ Recipients of clotting factor concentrates before 1987</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Men who have sex with men</td>
<td>▪ Recipients of blood transfusions or donated organs before July 1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Injection drug users</td>
<td>▪ Long-term hemodialysis patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Patients with elevated liver enzymes (ALT/AST) of unknown etiology</td>
<td>▪ Persons with known exposures to HCV (e.g., healthcare workers after needlesticks)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Hemodialysis patients</td>
<td>▪ HIV-infected persons</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Persons needing immunosuppressive or cytotoxic therapy</td>
<td>▪ Children born to infected mothers (do not test before age 18 mos.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ HIV-infected persons</td>
<td>▪ Patients with signs or symptoms of liver disease (e.g., abnormal liver enzyme tests)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Donors of blood, plasma, organs, tissues, or semen</td>
<td>▪ Donors of blood, plasma, organs, tissues, or semen</td>
</tr>
</tbody>
</table>
Hepatitis C is caused by infection with the hepatitis C virus (HCV). An estimated 3.2 million people in the United States have hepatitis C, and many are not aware of their infection. An estimated 30,000 people are infected with hepatitis C every year. More than 75% of individuals who get infected with hepatitis C are not able to clear the virus from their system and develop a chronic lifelong infection. More than 15,000 people die from complications of chronic hepatitis C every year in the US.

**Natural history**

Hepatitis C virus attacks the liver. The liver is an important organ in the abdomen. Its functions include ridding the blood of toxins, breaking down nutrients into a form the body can use, and synthesizing proteins needed to help the blood and immune system function properly. Once the hepatitis C virus invades liver cells, our body’s immune system attacks the affected cells and kills them. This can cause liver scarring (or fibrosis) which can cause the liver to malfunction. Extensive scarring is called cirrhosis. Cirrhosis usually happens over a 20 to 30 year time period, although it can happen quicker in some individuals with HIV infection or other liver disease from alcohol or hepatitis B infection. A person may or may not have symptoms of liver disease until the damage is very severe. Long-standing hepatitis C infection is also a leading cause of liver cancer in the United States.

**Transmission**

Hepatitis C virus is spread when blood from an infected person gets into the blood of an uninfected person. The most common way this happens is by:

- sharing needles or other equipment used to inject drugs
- blood transfusions or organ transplants that occurred prior to 1992 (before a test was available to screen blood and organ donors for infection)
- long-term hemodialysis for kidney disease
- accidental needle sticks with blood from a person with HCV

Less common modes of transmission include:

- Spread of virus from mother to baby
- Getting body piercings or tattoos with needles that have not been adequately sterilized. This would most likely occur when this is done in prison, at home, or on the street
- Sharing personal items that might have blood on them, such as razors, toothbrushes or blood glucose monitoring supplies
- Inhaling/snorting illicit drugs, including cocaine
- Rarely, having unprotected sex with a person infected with hepatitis C. The risk of transmission among monogamous partners is extremely low. However, the risk of sexual transmission of the virus is greater among men who have sex with men, individuals with multiple sexual partners, and those who engage in rough sex where there is a possibility of bleeding
Hepatitis C is not spread by casual contact (shaking hands, hugging), kissing, sharing food or utensils, coughing or sneezing, mosquitos or other bug-bites, or animals.

**Persons at risk for hepatitis C infection**

HCV testing is recommended for anyone at increased risk for HCV infection, including:

- Persons born from 1945 through 1965
- Persons who have ever injected illegal drugs, even if person injected only once or many years ago
- Persons with a history of incarceration
- Persons with a history of unregulated tattoos or piercings
- Recipients of clotting factor concentrates made before 1987
- Recipients of blood transfusions or solid organ transplants before July 1992
- Persons who have ever received long-term hemodialysis treatment
- All persons with HIV infection
- Persons with signs or symptoms of liver disease (e.g., abnormal liver enzyme tests)
- Recipients of blood or organs from a donor who later tested HCV-positive
- Persons with known exposures to HCV, such as
  - health care workers after needlesticks involving HCV-positive blood
  - Children born to HCV-positive women

**Treatment**

Hepatitis C virus can be treated with medications called antivirals that can clear the virus from the body, slow down liver damage, and reduce the chances of developing cirrhosis. Antiviral treatment is not right for everyone. The decision to start antiviral therapy is made by a patient and their doctor, and depends on the type of hepatitis C virus (genotype), the status of the liver and other coexisting health conditions.

Treatment for hepatitis C virus has evolved substantially since the introduction of highly effective protease inhibitor therapies in 2011. Current available treatments involve 8-12 weeks of oral therapy with minimal side effects and the ability to achieve sustained virologic response (SVR). SVR is defined as the absence of detectable virus 12 weeks after completion of treatment, which is an indicator for cure of HCV infection. Current HCV therapies have a over 90% cure rate.

For a complete list of currently approved therapies by the Food and Drug Administration (FDA) to treat hepatitis C, visit [http://www.hepatitisc.uw.edu/page/treatment/drugs](http://www.hepatitisc.uw.edu/page/treatment/drugs)

**Diagnosis**

Accurate testing for HCV helps health care providers correctly identify persons who are currently infected with HCV and offer them appropriate preventive services, medical care, and treatment. It also
allows HCV-infected persons make informed decisions regarding their medical care and following healthy liver practices that can limit the progression of their disease.

This recommended testing sequence should be implemented by providers using the HCV rapid antibody test and who are following CDC guidance regarding screening for HCV infection. This is not intended to be used for the diagnosis of acute hepatitis C infection. If rapid HCV testing is being performed outside of a medical provider’s office, individuals with symptoms of acute liver disease (e.g., jaundice, fever, abdominal pain) should be referred to a licensed medical provider for assessment. The testing sequence for Hepatitis C is detailed below and can also be visualized in Figure 1.

1) Rapid (or laboratory-conducted assay for HCV antibody) - These tests detect antibodies produced by a person against HCV.

   **Non-reactive** = no HCV antibody detected. This could indicate that a person is not infected with HCV, is in the Window Period (discussed below), or, if the person is immunocompromised, may not have the ability to develop antibodies against HCV.

   **Window Period** = the time period after HCV infection when antibodies have not yet been produced at a high enough level to be detected by available tests. Most HCV infected individuals (90%) develop antibodies between 4-12 weeks after infection. 97% of HCV infected persons have developed antibodies within 6 months. If an individual’s exposure falls within this time frame or is continuous (e.g., ongoing injection drug use), the Window Period is a concern. If client is being tested because of exposure within past 6 months, referral for HCV nucleic acid testing, or follow-up antibody testing is recommended.

   **Reactive** = Current HCV infection, past HCV infection that has resolved, or false positivity. This person should be referred to a health-care provider for performance of a nucleic acid test (NAT).

2) HCV nucleic acid test (NAT) – This test detects the presence of the hepatitis C virus in the blood. It may also be referred to as a HCV RNA polymerase-chain reaction (PCR) test. A person should be referred for HCV NAT if rapid or laboratory conducted HCV antibody test is positive, if a person has had exposure within the past 6 months or has clinical evidence of HCV disease, or if there is concern regarding the handling or storage of the test specimen.

   **RNA detected** = current HCV infection. Any person with these results should be linked to medical care and results reported to the local health department.

   **RNA not detected** = past, resolved HCV infection or false HCV antibody positivity. Further testing may be indicated as is medically appropriate.
Prevention

There currently is no vaccine for HCV. The risk of infection can be reduced by using safer injection practices, following infection control guidelines in healthcare settings, and not sharing personal items such as razors, toothbrushes, nail clippers or blood glucose monitors. In persons infected with HCV, healthy liver practices, such as eliminating alcohol intake, and vaccination against hepatitis A and B viruses can reduce the risk of developing liver damage.

PROTOCOL FOR PERFORMING RAPID HEPATITIS C TESTING

Pre-test client assessment

The tester should ask the following questions of the client:

1) abdominal pain, fatigue, loss in appetite, change in stools, excess bleeding

   Any signs or symptoms of hepatitis in past 3 months - including jaundice, nausea, vomiting,

   - if a client is currently having any of these symptoms, they may have acute hepatitis. They should be referred to a licensed medical provider for HCV diagnostic testing and further diagnostic evaluation including testing for hepatitis A, hepatitis B and other causes. The testing facility should also contact their local health department to notify them of a possible acute case.
3) Medication history – including NSAIDs, aspirin, Tylenol, statins, herbal or other dietary supplements

4) Medical history – including any history of HIV, STDs, liver or gallbladder problems, diabetes, bleeding problems, history of heavy alcohol use

5) Ever tested for hepatitis C before? Did a doctor ever tell them they had chronic HCV infection? Confirm if client is linked to care, and if not, make a referral. If previously HCV antibody positive, refer to provider capable of confirmatory testing. If not previously diagnosed with HCV or unsure, offer test.

**Pre-test counseling**

The pre-test counseling session includes basic HCV education, a review of the client’s risk assessment, and should help the client to consider appropriate risk reduction activities. This can take place during the 20 minute waiting period. Hepatitis C education can include audio/visual materials and printed fact sheets/brochures. Language barriers and low literacy are considerations in selecting appropriate educational materials. Components of pre-test counseling are:

1) **Establish rapport** - Developing trust is key to a successful interaction. Individuals conducting testing should convey concern, respect and empathy towards the client. Information provided to the client should include an introduction to the tester’s role, the purpose of testing, and the confidentiality of the client-tester interaction. An opportunity should be made for the client to ask questions.

2) **Educate regarding hepatitis C** - The tester should first assess the client’s knowledge regarding hepatitis C. Based on the client’s knowledge base, the tester should provide additional information regarding hepatitis C, particularly that blood exposure is the primary route of transmission. The tester should have adequate background knowledge to be able to address questions regarding the difference between hepatitis A, B and C viruses, HIV and other STDs. Information regarding the potential seriousness of HCV, including complications such as cirrhosis and liver cancer, should be provided. Misconceptions should be corrected.

3) **Assess client risk factors** - Testers should perform a standardized risk assessment for each client. A sample risk assessment form is provided in Appendix I. Some individuals may have current risk factors (e.g., ongoing injection drug use) and may benefit from referral to appropriate medical/social services (e.g., HIV, STD testing, substance abuse programs, syringe service programs, hepatitis A and B vaccine). Such discussions should occur in a compassionate, nonjudgmental manner. Others may have had risk factors in the past (e.g., past injection drug use, blood transfusion before 1992) or were born between 1945-1965. Some testing sites may also be performing risk assessment for STDs, HIV, and hepatitis B infection. Risk assessment for hepatitis C should be integrated into those efforts.

4) **Provide information on HCV antibody testing** - The meaning of reactive and non-reactive results should be introduced. The need for multiple tests in order to confirm HCV infection, including referral to a provider who can perform confirmatory testing, should be explained. The difference between antibodies and tests for current presence of the virus should be covered. The concept of the Window Period should be introduced, particularly emphasizing the need to retest in 6 months if non-reactive but with
recent or ongoing exposures. The importance of testing should be discussed. Benefits to testing include reassurance if not infected and early referral to medical care if infected. The tester should let the client know that rapid HCV antibody test results will be provided today. The client should be provided ample opportunity for asking questions.

**Specimen collection and test kit operation**

Package insert from OraQuick HCV Rapid Antibody Test is included in Appendix B.

**Disclosure and post-test counseling**

The post-test counseling session includes provision of HCV test results to the client. This should include education regarding the meaning of the results. Arrangements for confirmatory testing, medical referrals and referrals for applicable social services should be made. Results should be given in a neutral tone, in an empathetic non-judgmental manner by the same staff member as performed the test. Results should be provided in a private environment and adequate time should be allowed for the client to process the results, ask questions and receive appropriate referrals. The client should also be provided with a copy of HCV test results. This test result form should include the result as well as the meaning of the result. Separate sample forms for reactive and non-reactive results are available in Appendix F,G.

**Disclosure of non-reactive result**

A non-reactive result means that no HCV antibody was detected in the client’s blood. This could indicate that a person is not infected with HCV, is in the Window Period, or if the person is immunocompromised, may not have the ability to develop antibodies against HCV. A client should be allowed to express relief. The meaning of these results should be outlined for the client and tailored based on their risk factors. For instance, a client with ongoing exposure should receive information regarding the Window Period and developing a plan for re-testing and risk reduction.

Clients may only be interested in receiving their test results. However, post-test counseling is still important for clients with non-reactive results. Clients should again be provided with information on how to prevent HCV infection as knowledge regarding HCV transmission is often limited. It should be emphasized that non-reactive results do not mean they are immune to HCV infection in the future. The difference between Hepatitis A, B and C should be re-iterated, including the need for hepatitis A and/or hepatitis B vaccination.

The tester should verify that the client understands their HCV test results. The client’s risk behaviors should be acknowledged, and opportunities for risk reduction should be addressed. The client should leave with a list of resources, for instance, for STD testing, HIV testing and/or substance abuse programs.

**Disclosure of reactive result**
A reactive result means that antibodies to HCV were detected in the client’s blood. This means they have been infected with Hepatitis C virus at some time and may still be infected. Clients with reactive rapid HCV antibody results need a second blood test, the HCV NAT, to determine if they are currently infected or have cleared virus on their own. This type of testing can only be ordered by a medical provider.

Test results should be delivered in a neutral tone. Testing staff should notify the facility manager that they will be delivering a reactive result in order to accommodate additional time for counseling and referrals. The client should be allowed time to process the result. Upon receiving the result, the client may have an emotional reaction. They may ask many questions and want information right away, or they may not know what to say. If the client expresses fear regarding the result, they should be reassured that getting this test gives them information that will allow them to protect their health. While the seriousness of these results should be conveyed, the tester should explain that HCV progresses slowly and many people have no symptoms or mild symptoms for many years.

After the client has had the chance to process the result, additional information regarding hepatitis C infection should be provided, including what “hepatitis” is, how HCV is transmitted, and what the antibody result means. The need for a second test, the HCV NAT, should be addressed. The tester should verify that the client understands that the antibody test alone does not tell them whether or not they are currently infected.

The client should be advised to behave as though they are infected with hepatitis C prior to confirmatory testing. This includes reviewing key messages regarding how to reduce the chances of HCV transmission to others. Safe liver practices should also be reviewed such as reducing alcohol intake, and hepatitis B and hepatitis A vaccination as appropriate. Furthermore, the client should leave with a list of resources, for instance, for STD testing, HIV testing, and substance abuse programs.

**Referral process**

The details of the referral process should be discussed with clients with a reactive HCV antibody result. They should be told that they will be sent to another health care provider for the confirmatory HCV NAT which can detect the hepatitis C virus genetic material in the blood and determine whether or not they are currently infected. The testing logistics, including who will perform the test, and when and where the test will be performed, should be reviewed. Details regarding the appointment, or how they will be contacted to schedule their appointment, should be provided verbally and in writing- for instance on the sample reactive test results report sheet (Appendix G). Transportation to and from the appointment as well as appointment cost should be discussed. Facilities may have referral relationships with one or multiple health care providers. Consideration should be given to identifying referral providers who are convenient and affordable for their client population.

If possible, the client should be scheduled for a referral appointment while still at the testing facility. If this is not feasible, they should be advised they will be contacted by staff at the testing or referral facility regarding appointment scheduling. The client’s preferred contact phone number should be obtained.
Testing facility staff should maintain a referral log for reactive clients. Each facility should establish a follow-up procedure to assess whether or not reactive clients present for referral and their confirmatory test results.

**Disclosure of invalid result**

An invalid test result means the test was unable to determine if the result was reactive or non-reactive. This can occur when the internal control line on the test does not appear, or the lines are not appropriately aligned in the result window. A client with this result should be offered a retest. If the retest is invalid, the facility should contact OraSure Technology Customer Service at 1-800-672-7873.
REFERENCES:


APPENDICES:

A: MDHHS contact information
B: Rapid HCV testing procedures
C: Hepatitis C resources
D: Local health department listing
E: Rapid HCV reporting form and summary sheet
F: Sample Client non-reactive results reporting form
G: Sample Client reactive results reporting form and referral form
H: Other client referral resources
I: Sample HCV risk assessment form
J: Facility preparation checklist
Appendix A

**Michigan Department of Health and Human Services (MDHHS) contacts**

**MDHHS Viral Hepatitis Surveillance and Prevention Unit**
Phone: 517-335-8165  
Fax: 517-335-8263  
Email: [MDHHS-Hepatitis@michigan.gov](mailto:MDHHS-Hepatitis@michigan.gov)  
Web: [www.michigan.gov/hepatitis](http://www.michigan.gov/hepatitis)

**MDHHS Bureau of Laboratories**
Phone: 517-335-8063  
Fax: 517-335-9631  
Email: [MDHHSLab@michigan.gov](mailto:MDHHSLab@michigan.gov)  
Web: [www.michigan.gov/mdhslab](http://www.michigan.gov/mdhslab)

**MDHHS Regional Epidemiologists**

<table>
<thead>
<tr>
<th>Region</th>
<th>Counties</th>
<th>Name</th>
<th>Phone</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Clinton, Eaton, Gratiot, Hillsdale, Ingham, Jackson, Lenawee, Livingston, Shiawassee</td>
<td>Meghan Weinberg</td>
<td>517-749-2153</td>
<td><a href="mailto:WeinbergM1@michigan.gov">WeinbergM1@michigan.gov</a></td>
</tr>
<tr>
<td>2N</td>
<td>Macomb, Oakland, St. Clair</td>
<td>Nicole Parker-Strobe</td>
<td>517-930-6906</td>
<td><a href="mailto:ParkerStrobeN@michigan.gov">ParkerStrobeN@michigan.gov</a></td>
</tr>
<tr>
<td>2S</td>
<td>Detroit City, Monroe, Washtenaw, Wayne</td>
<td>Joyce Lai</td>
<td>517-930-6958</td>
<td><a href="mailto:LaiJ@michigan.gov">LaiJ@michigan.gov</a></td>
</tr>
<tr>
<td>3</td>
<td>Alcona, Arenac, Bay, Genesee, Gladwin, Huron, Iosco, Lapeer, Midland, Ogemaw, Oscoda, Saginaw, Sanilac, Tuscola</td>
<td>Tim Bolen</td>
<td>517-930-6910</td>
<td><a href="mailto:BolenT1@michigan.gov">BolenT1@michigan.gov</a></td>
</tr>
<tr>
<td>5</td>
<td>Allegan, Barry, Berrien, Branch, Calhoun, Cass, Kalamazoo, St. Joseph, Van Buren</td>
<td>Bethany Reimink</td>
<td>517-719-0407</td>
<td><a href="mailto:ReiminkB@michigan.gov">ReiminkB@michigan.gov</a></td>
</tr>
<tr>
<td>6</td>
<td>Clare, Ionia, Isabella, Kent, Lake, Mason, Mecosta, Montcalm, Muskegon, Newaygo, Oceana, Osceola, Ottawa</td>
<td>Fatema Mamou</td>
<td>517-204-6086</td>
<td><a href="mailto:MamouF@michigan.gov">MamouF@michigan.gov</a></td>
</tr>
<tr>
<td>7</td>
<td>Alpena, Antrim, Benzie, Charlevoix, Cheboygan, Crawford, Emmet, Grand Traverse, Kalkaska, Leelanau, Manistee, Missaukee, Montmorency, Otsego, Presque Isle, Roscommon, Wexford</td>
<td>Roger Racine</td>
<td>517-930-6914</td>
<td><a href="mailto:RacineR@michigan.gov">RacineR@michigan.gov</a></td>
</tr>
<tr>
<td>8</td>
<td>Alger, Baraga, Chippewa, Delta, Dickinson, Gogebic, Houghton, Iron, Keweenaw, Luce, Mackinac, Marquette, Menominee, Ontonagon, Schoolcraft</td>
<td>Scott Schreiber</td>
<td>517-930-3089</td>
<td><a href="mailto:SchreiberS@michigan.gov">SchreiberS@michigan.gov</a></td>
</tr>
</tbody>
</table>
Appendix B

Linking People to Care

Step-by-Step Instructions For OraQuick® HCV Rapid Antibody Test

Complexity: WAIVED for fingerstick whole blood and venipuncture whole blood.

A Certificate of CLIA Waiver is required to perform the test in a waived setting. Additional CLIA waiver information is available at the Centers for Medicare and Medicaid website at www.cms.hhs.gov/CLIA or from your state health department.

Failure to follow the instructions, or modifications to the test instructions, will result in the test no longer meeting the requirement for Waived Classification and will be subject to all applicable CLIA requirements.

- These instructions are only a Reference Guide. For complete information including Instructions, Precautions, and Limitations of the test, refer to the OraQuick® HCV Rapid Antibody Test Package Insert.
- Read these instructions completely before using the product. Follow the instructions carefully when performing testing. Not doing so may result in inaccurate test results.
- Before performing testing, all operators MUST read and become familiar with Universal Precautions for Prevention of Transmission of Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C Virus, and other Bloodborne Pathogens in Healthcare Settings. ¹²

INTENDED USE:
The OraQuick® HCV Rapid Antibody Tests is a single-use immunoassay for the qualitative detection of antibodies to Hepatitis C virus (anti-HCV infingerstick whole blood specimens and venipuncture whole blood specimens) in sera, sodium heparin, lithium heparin, and sodium citrate from individuals 15 years or older. The OraQuick® HCV Rapid Antibody Test results, in conjunction with other laboratory results and clinical information, may be used to provide evidence of infection with Hepatitis C virus or associated disease not determined in persons with signs or symptoms of Hepatitis C and in persons at risk for Hepatitis C Infection.

WARNING: This assay has not been FDA approved for use in patient populations without signs, symptoms, or not at risk for Hepatitis C Infection.

Not for use in screening whole blood, plasma, or tissue donors. Performance characteristics have not been established for testing a pediatric population less than 15 years of age or for pregnant women.

If you are a new operator, before proceeding you MUST be able to correctly interpret the OraQuick® HCV Visual Reference Panel prior to using the OraQuick® HCV Rapid Antibody test.

Failure to read at low intensities can result in the inability to detect specimens near the limit of detection of the OraQuick® HCV Rapid Antibody Test and may result in false negative results.

NOTE: Handle all blood specimens and materials contacting specimens as if capable of transmitting infectious agents. Dispose of all test specimens and materials used in the test procedure in a biohazard container.¹

FOR IN VITRO DIAGNOSTIC USE

THE FOLLOWING ITEMS ARE NEEDED TO DO THE TEST:
The OraQuick® HCV Rapid Antibody Test Consists of a Divided Pouch Containing the Following:
- Single-use test device (including an absorbent pad)
- Developer solution vial (containing 750 ml)

NOTE: The pouch is divided into two chambers. One chamber holds the Test Device while the other chamber holds the Developer Solution Vial.

Materials Provided in the Kit:
- Reusable Test Stands
- Package Insert
- Specimen Collection Loops

Materials Required But Not Provided:
- Timer or watch capable of timing 20 to 40 Minutes
- Materials required for venipuncture whole blood specimen collection
- OraQuick® HCV Rapid Antibody Test Kit Controls
- Biohazard waste container
- Sterile lancet to obtain a fingerstick whole blood specimen
- OraQuick® HCV Rapid Antibody Test Kit Controls

EXTERNAL QUALITY CONTROL
OraQuick® HCV Rapid Antibody Test Kit Controls are available separately for use only with OraQuick® HCV Rapid Antibody Test. The Kit Controls are specifically formulated and manufactured to ensure performance of the test, and are used to verify your ability to properly perform and test and interpret the results. Refer to the kit control package insert for complete instructions.

Run the Kit Controls under the following circumstances:
- Each new operator prior to performing testing on patient specimen,
- When opening a new test kit,
- Whenever a new shipment of test kits is received,
- If the temperature of the test kit storage area falls outside of 2°–30°C (36°–86°F),
- If the temperature of the testing area falls outside of 15°–37°C (59°–99°F),
- At periodic intervals as dictated by the user facility.

Test Procedure for Kit Controls
1. Open the kit control vial containing the control reagent.
2. Insert the rounded end of an unused specimen collection loop into the vial of control reagent, visually inspect the loop to make sure that it is completely filled with the control reagent. Use separate unused specimen collection loops for each control reagent.
3. Immediately immerse the control reagent filled Specimen Collection Loop into the Developer Vial. Use the Specimen Collection Loop to stir the specimen in the developer solution. Remove the specimen collection loop from the Developer vial and discard the used loop in a biohazard waste container.
4. Follow step 3 “testing procedure for additional instruction.”

SET UP YOUR WORKSPACE
- Gather all the materials you will need.
- Allow the test kit to come to operating temperature (15°-37°C; 59°-99°F) before use.
- Refer to the External Quality Control section above to determine when the kit controls should be run.
- Set an OraQuick® HCV Reusable Test Stand ("Stand") on your workspace. Use only the Stand provided.
- Disposable gloves are needed when performing the test.

GENERAL TEST PREPARATION
- If you are a new operator, you MUST be able to interpret all devices provided in the OraQuick® HCV Visual Reference Panel prior to using the OraQuick® HCV Rapid Antibody Test.
- Allow all components to come to operating temperature (15°-37°C, 59°-99°F).
- Place the reusable Test Stand on your workspace. Use only the Stand provided with the OraQuick® HCV Rapid Antibody Kit. Set up your timer for 20 to 40 minutes but DO NOT start.
- Do not open the pouch until you are ready to perform a test. Check the pouch for damage or holes. Discard the pouch if it is damaged (see picture A1).
- After opening the pouch, check for an absorbent pad. If it is not present or appears damaged, discard the pouch and open a new one (see picture A2).
- Hold the Developer Solution Vial firmly in your hand, remove the cap by noting it back and forth while pulling it off. Set the cap aside. Slide the Vial into the slots of one of the slots in the Stand (see picture A3).
- Leave the OraQuick® HCV test device in the pouch until testing is started. Refer to Step 3 in the Testing Procedure section.
- DO NOT cover the 2 holes on the back of the OraQuick® HCV Test Device with labels or other materials. Blocking the holes may cause an invalid result.
Appendix B

SPECIMEN COLLECTION PROCEDURE – FINGERSTICK WHOLE BLOOD

Step 1A – COLLECT
- Using an antiseptic wipe, clean the finger of the person being tested. Allow the finger to air dry.
- Using a sterile lancet, puncture the skin just off the center of the finger pad.
- Hold the finger downward. Apply gentle pressure to the side of the puncture. Avoid squeezing the finger to make it bleed (see picture 87).
- Wipe away the first drop of blood with a sterile gauze pad. Allow a new drop of blood to form.
- Pick up an unused Specimen Collection Loop ("Loop") by the thick "handle" end (see picture 87).
- Put the "rounded" end of the loop on the drop of blood (see picture 86). Make sure that the Loop is completely filled with blood (see picture 86).

NOTE: If the Loop is dropped or comes in contact with any other surface, discard it in a biohazard waste container. Get a new loop for the collection of the blood sample.

VENIPUNCTURE WHOLE BLOOD

Step 1B – COLLECT
- Using standard venipuncture procedure, collect a whole blood sample using a tube containing any of the following anticoagulants: 3.8% (w/v) sodium citrate (green top) or sodium citrate (light blue top). Other anticoagulants have not been tested and may give an incorrect result. If the specimen is not tested at the time of collection, the whole blood may be stored at 2°–4°C (36°–40°F) for up to 7 days or at 15°–30°C (60°–86°F) for up to 3 days.
- Prior to testing, mix the blood tube gently by inversion several times to ensure a homogenous specimen.
- Pick up an unused Specimen Collection Loop ("Loop") by the thick "handle" end (see picture 87).
- Put the "rounded" end of the Loop into the tube of blood (see picture 86). Make sure the Loop is completely filled with blood (see picture 87).

NOTE: If the Loop is dropped or comes in contact with any other surface, discard it in a biohazard waste container. Get a new loop for the collection of the blood sample.

TESTING PROCEDURE

Step 2 – MIX
- Immediately mix the blood-filled end of the Loop all the way into the Vial (see picture 86).
- Use the Vial to stir the blood sample in the developer solution ("Solution") (see picture 89).
- Remove the used Loop from the Solution. Throw the used Loop away in a biohazard waste container.
- Check the solution to make sure that it appears pink. This means that the blood was correctly mixed into the solution (see picture 88). If the solution is not pink, discard all of the test materials in a biohazard waste container. Start the test over. Use a new Pouch and a new blood sample.

Step 3 – TEST
- Remove the Device from the Pouch. DO NOT touch the Flat Pad (see picture 87).
- Check to make sure that an Absorbent Packet is included with the Device (see picture 87). If no Absorbent Packet is present, discard the Device and obtain a new Pouch for testing.
- Insert the Flat Pad of the Device all the way into the Vial containing the blood sample (see picture 88). Make sure that the Flat Pad touches the bottom of the Vial. The Result Window on the Device should be facing you (see picture 88).
- Start timing the test (see picture 87). DO NOT remove the Device from the Vial while the test is running. Ink fluid will appear and travel up the Result Window. The pink fluid will gradually disappear as the test develops.
- Wait 20 minutes.
- Read the results after 20 minutes but not more than 40 minutes in a fully lighted area.
- Refer to the Test Result and Interpretation sections in these instructions.
Appendix B

Test Result and Interpretation - Refer to the Result Window on the Test Device

Caution: Adequate lighting required. Color blindness may affect the ability to interpret test results.

Reactive: Lines in C and T Zones

Test is Reactive if:
- A line appears in the C zone and a line appears in the T zone.
- Lines may vary in intensity, two lines must be present for a "reactive" result.
- The test is reactive regardless of how faint these lines appear.
- A reactive test result means that HCV antibodies have been detected in the specimen. Patient is presumed to be infected with HCV.
- Follow appropriate guidelines for supplemental testing.

Non-Reactive: Lines in C Zone Only

Test is Non-Reactive if:
- A line appears in the C Zone and no line appears in the T Zone.
- A Non-Reactive test result means that HCV antibodies were not detected in the specimen.
- Patient is presumed not to be infected with HCV.

Invalid: No Lines in C Zone or Partially Developed Lines

Test is Invalid if:
- No line appears in the C Zone, or
- A pink background obscures the results during the 20-30 minute read time, or
- Any partial line appears on one side of the C or T zones,
- An invalid test result means that there was a problem running the test either related to the Specimen or to the Test Device.
- An invalid result cannot be interpreted. Repeat the test with a new pouch and a new Specimen.
- Contact OraSure Technologies Customer Service if you are unable to get a valid test result upon repeat testing.

General Test Clean Up
- Dispose of the used test materials in a biohazard waste container.
- Change your gloves between each test to prevent contamination. Throw away the used gloves in a biohazard waste container.
- Use a freshly prepared 10% solution of bleach to clean up any spills.

For answers to questions or technical assistance regarding the OraQuick HCV Rapid Antibody Test, call: 1-800-ORASURE (800-672-7873) or visit our web site: www.orasure.com

For answers to questions or technical assistance regarding the OraQuick HCV Rapid Antibody Test, call: 1-800-ORASURE (800-672-7873) or visit our web site: www.orasure.com

OraSure Technologies
220 East Post Street
Boyers, PA 17513 USA
phone: 800.ORASURE
web: www.orasure.com

©2005, 2011 OraSure Technologies, Inc. All rights reserved. This product is solely for use by OraSure Technologies, Inc. and is not intended for distribution. This test is not intended for diagnostic use in the United States. This product is not approved for sale in the United States. This product is approved for sale in selected countries only. For more information, please contact OraSure Technologies, Inc. at www.orasure.com
HEPATITIS C RESOURCES

**General Hepatitis C information**

MDHHS Hepatitis C website:

[www.michigan.gov/hepatitis](http://www.michigan.gov/hepatitis)

CDC Hepatitis C website:


CDC Hepatitis C Patient Education resources:

[www.cdc.gov/hepatitis/HCV/PatientEduHCV.htm](http://www.cdc.gov/hepatitis/HCV/PatientEduHCV.htm)

HCV Advocate:

[www.hcvadvocate.org/](http://www.hcvadvocate.org/)

CDC Guide to Comprehensive Hepatitis C Counseling and Testing:


**Health professional HCV training:**

HCV Advocate training resources:

[www.hcvadvocate.org/training-resources/](http://www.hcvadvocate.org/training-resources/)

University of Washington Hepatitis training module:

[www.depts.washington.edu/hepstudy/](http://www.depts.washington.edu/hepstudy/)

CDC Hepatitis serology training:

[www.cdc.gov/hepatitis/Resources/Professionals/Training/Serology/training.htm](http://www.cdc.gov/hepatitis/Resources/Professionals/Training/Serology/training.htm)

Know Hepatitis.org training modules:

[www.knowhepatitis.org/training/center](http://www.knowhepatitis.org/training/center)
Appendix D

Michigan Local Health Departments

<table>
<thead>
<tr>
<th>COUNTY</th>
<th>HEALTH DEPT.</th>
<th>CO. OFFICE</th>
<th>AREA</th>
<th>PHONE</th>
<th>FAX</th>
<th>COUNTY</th>
<th>HEALTH DEPT.</th>
<th>CO. OFFICE</th>
<th>PHONE</th>
<th>FAX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcona</td>
<td>District 2</td>
<td>Houghton</td>
<td>906</td>
<td>682-7382</td>
<td>428-9410</td>
<td>Alcona</td>
<td>District 2</td>
<td>Houghton</td>
<td>906</td>
<td>682-7382</td>
</tr>
<tr>
<td>Allegan</td>
<td>Allegan County</td>
<td>Allegan</td>
<td>269</td>
<td>673-5411</td>
<td>673-2163</td>
<td>Allegan</td>
<td>Allegan County</td>
<td>Allegan</td>
<td>269</td>
<td>673-5411</td>
</tr>
<tr>
<td>Alpena</td>
<td>District 4</td>
<td>Alpena</td>
<td>989</td>
<td>356-4507</td>
<td>356-3529</td>
<td>Alpena</td>
<td>District 4</td>
<td>Alpena</td>
<td>989</td>
<td>356-4507</td>
</tr>
<tr>
<td>Ann Arbor</td>
<td>Health Dept. of NW MI</td>
<td>Bellmore</td>
<td>261</td>
<td>338-8670</td>
<td>547-6336</td>
<td>Ann Arbor</td>
<td>Health Dept. of NW MI</td>
<td>Bellmore</td>
<td>261</td>
<td>338-8670</td>
</tr>
<tr>
<td>Arenac</td>
<td>Gen'l MI DH D</td>
<td>Standish</td>
<td>898</td>
<td>846-6541</td>
<td>846-0341</td>
<td>Arenac</td>
<td>Gen'l MI DH D</td>
<td>Standish</td>
<td>898</td>
<td>846-6541</td>
</tr>
<tr>
<td>Baraga</td>
<td>Western UP Dist</td>
<td>L'Anse</td>
<td>906</td>
<td>524-6142</td>
<td>524-6144</td>
<td>Baraga</td>
<td>Western UP Dist</td>
<td>L'Anse</td>
<td>906</td>
<td>524-6142</td>
</tr>
<tr>
<td>Baraga</td>
<td>Barry-Eaton DH D</td>
<td>Hastings</td>
<td>269</td>
<td>798-4112</td>
<td>517-5461-6666</td>
<td>Baraga</td>
<td>Barry-Eaton DH D</td>
<td>Hastings</td>
<td>269</td>
<td>798-4112</td>
</tr>
<tr>
<td>Bay County</td>
<td>Bay City</td>
<td>Bay City</td>
<td>989</td>
<td>895-2039</td>
<td>895-2038</td>
<td>Bay County</td>
<td>Bay City</td>
<td>Bay City</td>
<td>989</td>
<td>895-2039</td>
</tr>
<tr>
<td>Berrien</td>
<td>Berrien Harbor</td>
<td>Harbor</td>
<td>269</td>
<td>926-7121</td>
<td>926-8129</td>
<td>Berrien</td>
<td>Berrien Harbor</td>
<td>Harbor</td>
<td>269</td>
<td>926-7121</td>
</tr>
<tr>
<td>Branch</td>
<td>Branch/Hills/St Jo</td>
<td>Coldwater</td>
<td>517</td>
<td>278-9561</td>
<td>278-9293</td>
<td>Branch</td>
<td>Branch/Hills/St Jo</td>
<td>Coldwater</td>
<td>517</td>
<td>278-9561</td>
</tr>
<tr>
<td>Calhoun</td>
<td>Calhoun FH</td>
<td>Battle Creek</td>
<td>269</td>
<td>989-6370</td>
<td>989-6488</td>
<td>Calhoun</td>
<td>Calhoun FH</td>
<td>Battle Creek</td>
<td>269</td>
<td>989-6370</td>
</tr>
<tr>
<td>Charlevoix</td>
<td>Health Dept. of NW MI</td>
<td>Charlevoix</td>
<td>231</td>
<td>547-6523</td>
<td>547-6338</td>
<td>Charlevoix</td>
<td>Health Dept. of NW MI</td>
<td>Charlevoix</td>
<td>231</td>
<td>547-6523</td>
</tr>
<tr>
<td>Cheboygan</td>
<td>District 4</td>
<td>Cheboygan</td>
<td>261</td>
<td>627-8550</td>
<td>899-356-3529</td>
<td>Cheboygan</td>
<td>District 4</td>
<td>Cheboygan</td>
<td>261</td>
<td>627-8550</td>
</tr>
<tr>
<td>Chippewa</td>
<td>Chippewa County</td>
<td>Sault Ste. Marie</td>
<td>906</td>
<td>635-1566</td>
<td>635-7081</td>
<td>Chippewa</td>
<td>Chippewa County</td>
<td>Sault Ste. Marie</td>
<td>906</td>
<td>635-1566</td>
</tr>
<tr>
<td>Clare</td>
<td>Gen'l MI DH D</td>
<td>Harrison</td>
<td>989</td>
<td>539-0711</td>
<td>539-4449</td>
<td>Clare</td>
<td>Gen'l MI DH D</td>
<td>Harrison</td>
<td>989</td>
<td>539-0711</td>
</tr>
<tr>
<td>Clinton</td>
<td>Mid-MI DH D</td>
<td>St. Johns</td>
<td>906</td>
<td>237-3111</td>
<td>227-3126</td>
<td>Clinton</td>
<td>Mid-MI DH D</td>
<td>St. Johns</td>
<td>906</td>
<td>237-3111</td>
</tr>
<tr>
<td>Crawford</td>
<td>District 10</td>
<td>Graying</td>
<td>989</td>
<td>348-7800</td>
<td>348-3436</td>
<td>Crawford</td>
<td>District 10</td>
<td>Graying</td>
<td>989</td>
<td>348-7800</td>
</tr>
<tr>
<td>Delta</td>
<td>Delta-Miss Dist</td>
<td>Escanaba</td>
<td>906</td>
<td>786-1111</td>
<td>786-8148</td>
<td>Delta</td>
<td>Delta-Miss Dist</td>
<td>Escanaba</td>
<td>906</td>
<td>786-1111</td>
</tr>
<tr>
<td>Eaton</td>
<td>Barry-Eaton DH D</td>
<td>Charlotte</td>
<td>517</td>
<td>541-2641</td>
<td>541-2666</td>
<td>Eaton</td>
<td>Barry-Eaton DH D</td>
<td>Charlotte</td>
<td>517</td>
<td>541-2641</td>
</tr>
<tr>
<td>Emmet</td>
<td>Health Dept. of NW MI</td>
<td>Petoskey</td>
<td>231</td>
<td>347-6014</td>
<td>547-6238</td>
<td>Emmet</td>
<td>Health Dept. of NW MI</td>
<td>Petoskey</td>
<td>231</td>
<td>347-6014</td>
</tr>
<tr>
<td>Genesee</td>
<td>Genesee County</td>
<td>Flint</td>
<td>810</td>
<td>257-1037</td>
<td>257-3247</td>
<td>Genesee</td>
<td>Genesee County</td>
<td>Flint</td>
<td>810</td>
<td>257-1037</td>
</tr>
<tr>
<td>Ionia</td>
<td>Ionia County</td>
<td>Ionia</td>
<td>616</td>
<td>527-5341</td>
<td>527-2028</td>
<td>Ionia</td>
<td>Ionia County</td>
<td>Ionia</td>
<td>616</td>
<td>527-5341</td>
</tr>
<tr>
<td>Iron County</td>
<td>District 2</td>
<td>Tawas</td>
<td>906</td>
<td>382-6183</td>
<td>382-5111</td>
<td>Iron County</td>
<td>District 2</td>
<td>Tawas</td>
<td>906</td>
<td>382-6183</td>
</tr>
<tr>
<td>Isabella</td>
<td>Cent' MI DH D</td>
<td>Mt. Pleasant</td>
<td>989</td>
<td>773-5921</td>
<td>773-4319</td>
<td>Isabella</td>
<td>Cent' MI DH D</td>
<td>Mt. Pleasant</td>
<td>989</td>
<td>773-5921</td>
</tr>
<tr>
<td>Jackson</td>
<td>Jackson County</td>
<td>Jackson</td>
<td>517</td>
<td>768-1662</td>
<td>768-4256</td>
<td>Jackson</td>
<td>Jackson County</td>
<td>Jackson</td>
<td>517</td>
<td>768-1662</td>
</tr>
<tr>
<td>Kalamazoo</td>
<td>Kalamazoo County</td>
<td>Kalamazoo</td>
<td>269</td>
<td>373-5267</td>
<td>373-5060</td>
<td>Kalamazoo</td>
<td>Kalamazoo County</td>
<td>Kalamazoo</td>
<td>269</td>
<td>373-5267</td>
</tr>
<tr>
<td>Kalkaska</td>
<td>Kalkaska</td>
<td>Kalkaska</td>
<td>231</td>
<td>258-8609</td>
<td>258-2085</td>
<td>Kalkaska</td>
<td>Kalkaska</td>
<td>Kalkaska</td>
<td>231</td>
<td>258-8609</td>
</tr>
<tr>
<td>Kent</td>
<td>Kent County</td>
<td>Grand Rapids</td>
<td>616</td>
<td>632-7228</td>
<td>632-7083</td>
<td>Kent</td>
<td>Kent County</td>
<td>Grand Rapids</td>
<td>616</td>
<td>632-7228</td>
</tr>
<tr>
<td>Kent County</td>
<td>Kent County</td>
<td>Kent City</td>
<td>231</td>
<td>775-9942</td>
<td>775-4127</td>
<td>Kent County</td>
<td>Kent County</td>
<td>Kent City</td>
<td>231</td>
<td>775-9942</td>
</tr>
</tbody>
</table>

### STATE OF MICHIGAN CONTACTS

<table>
<thead>
<tr>
<th>Department</th>
<th>Phone</th>
<th>Fax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunization Division</td>
<td>517-335-8159</td>
<td>517-335-9685</td>
</tr>
<tr>
<td>Communicable Disease Division</td>
<td>517-335-0165</td>
<td>517-335-9683</td>
</tr>
<tr>
<td>Bureau of Laboratories</td>
<td>517-335-0693</td>
<td>517-335-9683</td>
</tr>
</tbody>
</table>

Updated January 2018
### Case Identification

<table>
<thead>
<tr>
<th>First:</th>
<th>Last:</th>
<th>Middle:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Street Address:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>City:</th>
<th>County:</th>
<th>State:</th>
<th>Zip:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Home Phone:</th>
<th>Cell/Other Phone:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(           )</td>
<td>(           )</td>
</tr>
</tbody>
</table>

### Case Demographics

<table>
<thead>
<tr>
<th>Sex:</th>
<th>Date of Birth</th>
<th>Age:</th>
<th>Age Units:</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Male</td>
<td>☐ Female</td>
<td>☐ Unknown</td>
<td>☐ Days</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Race (Check all that apply):</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Caucasian</td>
</tr>
<tr>
<td>☐ Asian</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hispanic Ethnicity:</th>
<th>Arab Ethnicity:</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Hispanic/Latino</td>
<td>☐ Arab</td>
</tr>
<tr>
<td>☐ Non-Hispanic/Latino</td>
<td>☐ Non-Arab</td>
</tr>
<tr>
<td>☐ Unknown</td>
<td>☐ Unknown</td>
</tr>
</tbody>
</table>

### Clinical Information

<table>
<thead>
<tr>
<th>Testing Date:</th>
<th>Test Result:</th>
</tr>
</thead>
<tbody>
<tr>
<td>_ _ / _ _ / _ _ _ _</td>
<td>☐ Positive</td>
</tr>
</tbody>
</table>

Is the patient experiencing any symptoms of Hepatitis C infection (e.g. fever, headache, malaise, anorexia, abdominal discomfort, diarrhea, nausea, vomiting)?

☐ Yes | ☐ No | ☐ Unknown

Is or was the patient jaundiced?

☐ Yes | ☐ No | ☐ Unknown

Has the patient ever been previously told they were positive for hepatitis C?

☐ Yes | ☐ No | ☐ Unknown

Was the patient counseled?:

☐ Yes | ☐ No | ☐ Unknown

Was the patient linked to care?:

☐ Yes | ☐ No | ☐ Unknown | If yes, where? ________________________________

### Testing Agency

<table>
<thead>
<tr>
<th>Name of Testing Agency:</th>
<th>Phone: (           )</th>
</tr>
</thead>
</table>

### Additional Information:

---

Reporting is expressly allowed under HIPAA and required by Michigan Public Act 368 of 1978, 333.5111. Report to local health departments within 24 hours (unless otherwise noted) if the agent is identified by clinical or laboratory diagnosis.
HCV Rapid Antibody Test – Summary Sheet

Please complete the tables below and send this Summary Sheet to the Viral Hepatitis Prevention and Surveillance Unit at MDHHS-Hepatitis@michigan.gov.

<table>
<thead>
<tr>
<th>Testing Agency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Testing Agency:</td>
</tr>
<tr>
<td>Phone: (          )</td>
</tr>
<tr>
<td>Name of Testing Event (if applicable):</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NUMBER OF TESTS PERFORMED</th>
<th>NUMBER OF PEOPLE SCREENED HCV ANTIBODY-POSITIVE</th>
<th>NUMBER OF PEOPLE LINKED TO CARE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Additional Comments/Information**
Rapid Hepatitis C Antibody Test Result

<table>
<thead>
<tr>
<th>Client Name:</th>
<th>Test Date: _ _ / _ _ / _ _ _ _</th>
</tr>
</thead>
<tbody>
<tr>
<td>Client Date of Birth:</td>
<td>_ _ / _ _ / _ _ _ _</td>
</tr>
<tr>
<td>Counselor/Tester Name:</td>
<td></td>
</tr>
</tbody>
</table>

The Hepatitis C Antibody result from the Rapid Hepatitis C Antibody Test is: □ NONREACTIVE

What does a non-reactive result mean?

- No antibodies to the Hepatitis C virus were found in your blood.
- You are most likely not infected with Hepatitis C at this time; however, it can take up to 6 months after being exposed to Hepatitis C for your body to make enough antibodies for this test to measure them.
- If you were exposed to Hepatitis C, or used drug injection or preparation equipment in the past 6 months, you should get tested again 6 months from now or 6 months from the day of your last exposure.
- This test result does not mean you cannot be infected with Hepatitis C in the future.

How do I STAY Hepatitis C Negative?

- Do not share needles, syringes, or other equipment (e.g. cookers, spoons, cotton, filters, and water) used to prepare or inject drugs. Do not re-use needles. Bleaching needles or syringes does not work to kill the Hepatitis C virus.
- Do not share personal items that could have infected blood on them, including toothbrushes, razors, or glucose monitoring equipment.
- Do not get tattoos, body art, or body piercings in a non-licensed, informal place (e.g. homes or jails).
- Practice safe sex.
Rapid Hepatitis C Antibody Test Result

| Client Name: | Test Date: __/__/____ |
| Client Date of Birth: __/__/____ |
| Counselor/Tester Name: |

The Hepatitis C Antibody result from the Rapid Hepatitis C Antibody Test is: □ REACTIVE

What does a reactive result mean?
- You have been infected with the Hepatitis C virus at some time and may still have the virus in your blood right now.
- Some people clear the virus from their bodies after infection, but most do not.

Next Steps
- To find out if you still have the virus in your blood, you need to have a second blood test called a HCV PCR test.
- To get the HCV PCR test, you need to see a doctor. If the test shows that you currently have hepatitis C virus in your blood, you will see the doctor again to talk about your liver health and treatment options.

How do I avoid spreading Hepatitis C to others?
- Do not share needles, syringes, or other equipment (e.g. cookers, spoons, cotton, filters, and water) used to prepare or inject drugs. Do not re-use needles. Bleaching needles or syringes does not work to kill the Hepatitis C virus.
- Do not share personal items that could have infected blood on them, including toothbrushes, razors, or glucose monitoring equipment.
- Do not get tattoos, body art, or body piercings in a non-licensed, informal place (e.g. homes or jails).
- Practice safe sex.

Referral Information:

It is important that you keep this appointment.

| Appointment Date: __/__/____ | Appointment Time: __:__ □ AM □ PM |
| Organization: |
| Contact Person: | Phone Number: (____) |
Client Referral Resources

HEALTH INSURANCE ENROLLMENT RESOURCES

- U.S. Health Insurance Marketplace
  www.healthcare.gov
- State of Michigan – Department of Insurance and Financial Services Consumer Marketplace Assistance
  www.michigan.gov/difs/0,5269,7-303-12902_35510-313357--,00.html
- Enroll Michigan – Find Local Help
  www.enrollmichigan.com/find-local-help/
- Michigan County Health Plans
  www.michigan.gov/mdhhs/0,5885,7-339-71547_2943_52115-203917--,00.html

FINANCIAL RESOURCES

- Free or Low-Cost Healthcare Resources
  www.michigan.gov/mdhhs/0,5885,7-339-71547_2943_52115----,00.html
- Vaccine Payment Assistance
  www.michigan.gov/documents/mdhhs/Helping_Adults_Pay_Vaccine_514117_7.pdf

SUPPORT GROUPS

- American Liver Foundation – Michigan Support Groups
  www.liverfoundation.org/alf-great-lakes/local-resources/#support-groups-in-michigan
- Hepatitis C Support Group – Southeast Michigan
  www.michigan.gov/mdhhs/0,5885,7-339-71550_2955_2976_66410-312781--,00.html

PROGRAM RESOURCES

- Michigan Harm Reduction/Syringe Service Programs
  www.nasen.org/directory/mi/
- Michigan Community Mental Health Services Programs
  www.michigan.gov/documents/cmh_8_1_02_37492_7.PDF

OTHER RESOURCES

- Regional Substance Abuse Coordinating Agencies
- HIV Counseling and Testing Locations
  www.miunified.org/Events/Testing

For a more comprehensive list of resources, visit www.michigan.gov/hepatitis
Sample Hepatitis C Risk Assessment Form

Read the following list of statements to your patient. After reading the complete list of statements below, ask your patient if any of the following statements are applicable. If your patient states at least one of the below statements are true, he or she should be tested for Hepatitis C.

1. You were born between 1945 and 1965.

2. You received clotting factor concentrates produced before 1987.

3. You have had a blood transfusion or organ transplant before 1992.

4. You have been on long-term hemodialysis.

5. You have received a tattoo or piercing outside of a regulated body art facility (e.g. at a party, on the street, in jail or prison, or at a friend’s house).

6. You have used intravenous or injectable drugs for non-medical purposes (even if only once or many years ago).

7. You have been incarcerated.

8. You have been told that you have elevated or abnormal liver enzymes.

9. You tested positive for HIV.

10. You have worked in a medical, dental, or public safety field where you may have been exposed to hepatitis C via a needlestick injury or to hepatitis C-infected blood.

11. You were born to a mother who was infected with hepatitis C.
Rapid Hepatitis C Antibody Testing – Facility Preparation Checklist

Testing Agency:

<table>
<thead>
<tr>
<th>No.</th>
<th>ITEM</th>
<th>COMPLETED (✓)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Valid CLIA Waiver obtained</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>Bloodborne pathogen training completed</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Quality assurance plan developed (including appropriate storage conditions for kit controls)</td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>Authorizing healthcare provider</td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>Written policies and procedures manual</td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>Referral relationship established for reactive results</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Local health department contacted and results reporting mechanism in place</td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>Referral resources for low-cost primary care, STD and HIV testing, substance abuse and mental health available</td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td>Testing supplies – kits, thermometer, timer, disinfectant solution, medical waste containers</td>
<td></td>
</tr>
<tr>
<td>9.</td>
<td>Referral tracking mechanism</td>
<td></td>
</tr>
<tr>
<td>10.</td>
<td>Client record storage and retention policy in place</td>
<td></td>
</tr>
<tr>
<td>11.</td>
<td>Staff test kit training</td>
<td></td>
</tr>
<tr>
<td>12.</td>
<td>Staff hepatitis C education and counseling training</td>
<td></td>
</tr>
</tbody>
</table>